Wall Street brokerages expect that Blueprint Medicines Corp (NASDAQ:BPMC) will report sales of $2.14 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Blueprint Medicines’ earnings, with the lowest sales estimate coming in at $1.13 million and the highest estimate coming in at $3.44 million. Blueprint Medicines reported sales of $1.63 million in the same quarter last year, which indicates a positive year over year growth rate of 31.3%. The firm is expected to announce its next quarterly earnings results on Wednesday, February 20th.
On average, analysts expect that Blueprint Medicines will report full year sales of $45.64 million for the current year, with estimates ranging from $44.61 million to $46.93 million. For the next fiscal year, analysts anticipate that the firm will post sales of $9.03 million, with estimates ranging from $3.62 million to $20.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Blueprint Medicines.
Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Tuesday, October 30th. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.09). Blueprint Medicines had a negative return on equity of 36.72% and a negative net margin of 455.15%. The firm had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.87 million. During the same period in the previous year, the business posted ($0.96) EPS. Blueprint Medicines’s revenue for the quarter was down 86.4% compared to the same quarter last year.
Several equities analysts recently commented on BPMC shares. ValuEngine downgraded Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 24th. Cowen restated a “buy” rating on shares of Blueprint Medicines in a research report on Sunday, October 7th. Wedbush restated an “outperform” rating and set a $101.00 target price on shares of Blueprint Medicines in a research report on Monday, October 22nd. BidaskClub upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Thursday, October 18th. Finally, Leerink Swann initiated coverage on Blueprint Medicines in a research report on Tuesday, September 25th. They issued an “outperform” rating and a $105.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $103.25.
Shares of NASDAQ:BPMC opened at $70.02 on Friday. Blueprint Medicines has a 1-year low of $44.58 and a 1-year high of $109.00. The company has a market cap of $3.07 billion, a PE ratio of -17.86 and a beta of 1.34. The company has a current ratio of 10.05, a quick ratio of 10.05 and a debt-to-equity ratio of 0.03.
In other news, CEO Jeffrey W. Albers sold 20,000 shares of Blueprint Medicines stock in a transaction on Monday, November 5th. The stock was sold at an average price of $63.49, for a total value of $1,269,800.00. Following the completion of the sale, the chief executive officer now directly owns 20,000 shares of the company’s stock, valued at approximately $1,269,800. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 3.15% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc increased its stake in shares of Blueprint Medicines by 3.1% in the 3rd quarter. Vanguard Group Inc now owns 3,735,390 shares of the biotechnology company’s stock valued at $291,584,000 after buying an additional 111,972 shares during the period. Marshall Wace North America L.P. acquired a new stake in shares of Blueprint Medicines in the 3rd quarter valued at $2,331,000. Marshall Wace LLP acquired a new stake in shares of Blueprint Medicines in the 3rd quarter valued at $11,579,000. Vanguard Group Inc. increased its stake in shares of Blueprint Medicines by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 3,735,390 shares of the biotechnology company’s stock valued at $291,584,000 after buying an additional 111,972 shares during the period. Finally, Teachers Advisors LLC increased its stake in shares of Blueprint Medicines by 2.6% in the 3rd quarter. Teachers Advisors LLC now owns 182,797 shares of the biotechnology company’s stock valued at $14,269,000 after buying an additional 4,600 shares during the period.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Featured Article: How Do Tariffs Affect Trade Balances?
Get a free copy of the Zacks research report on Blueprint Medicines (BPMC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.